In vitro functional interactions of acetylcholine esterase inhibitors and muscarinic receptor antagonists in the urinary bladder of the rat

Clinical and Experimental Pharmacology & Physiology
Uday K KilliG Tobin

Abstract

Obidoxime, a weak acetylcholine-esterase (AChE) inhibitor, exerts muscarinic receptor antagonism with a significant muscarinic M2 receptor selective profile. The current examinations aimed to determine the functional significance of muscarinic M2 receptors in the state of AChE inhibition, elucidating muscarinic M2 and M3 receptor interaction. In the in vitro examinations, methacholine evoked concentration-dependent bladder contractile and atrial frequency inhibitory responses. Although atropine abolished both, methoctramine (1 μmol/L) only affected the cholinergic response in the atrial preparations. However, in the presence of methoctramine, physostigmine, an AChE inhibitor, increased the basal tension of the bladder strip preparations (+68%), as well as the contractile responses to low concentrations of methacholine (< 5 μmol/L; +90-290%). In contrast to physostigmine, obidoxime alone raised the basal tension (+58%) and the responses to low concentrations of methacholine (< 5 μmol/L; +80-450%). Physostigmine concentration-dependently increased methacholine-evoked responses, similarly to obidoxime at low concentrations. However, at large concentrations (> 5 μmol/L), obidoxime, because of its unselective muscarinic receptor ant...Continue Reading

References

Jul 1, 1992·Toxicology and Applied Pharmacology·H P van HeldenO L Wolthuis
Jan 1, 1989·Archives of Toxicology·M G Hamilton, P M Lundy
Dec 1, 1984·Biochemical Society Transactions·S B MarstonC Smith
Jan 1, 1993·Pharmacology & Therapeutics·T C Marrs
Oct 1, 1995·British Journal of Pharmacology·P A LonghurstJ A Briscoe
Jan 1, 1996·Archives of Toxicology·H P van HeldenP L Bruijnzeel
Apr 26, 2000·British Journal of Pharmacology·R M Eglen, S R Nahorski
Jan 31, 2002·Naunyn-Schmiedeberg's Archives of Pharmacology·Hongxia ZhouAnne-Ulrike Trendelenburg
Dec 12, 2002·Journal of Toxicology. Clinical Toxicology·J Kassa
May 3, 2003·Pharmacology & Therapeutics·Chris J van Koppen, Björn Kaiser
Apr 28, 2004·The Journal of General Physiology·Alexander V ZholosThomas B Bolton
Nov 4, 2005·Proceedings of the American Thoracic Society·Kristen E Belmonte
Jan 25, 2007·Basic & Clinical Pharmacology & Toxicology·Daniel GiglioGunnar Tobin
Mar 20, 2009·Pharmacology·Daniel Giglio, Gunnar Tobin
Mar 30, 2010·Current Medicinal Chemistry·O SoukupK Kuca
May 7, 2010·Journal of Molecular Neuroscience : MN·David A Brown
Jul 27, 2011·Environmental Toxicology and Pharmacology·O SoukupG Tobin

❮ Previous
Next ❯

Citations

Jan 29, 2019·Frontiers in Physiology·Basu ChakrabartyMarcus J Drake

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.